BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a revised preliminary non-binding proposal letter (the "Revised Proposal Letter"), dated August 26, 2025, from a consortium ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock movement of Lakeshore Biosciences (LSB), indicating a positive trend in both revenue and net profit [1] - As of August 18, LSB's stock price increased by 3.36%, reaching $0.806 per share, with a total market capitalization of $33.2257 million [1] - Financial data shows that by March 31, 2025, LSB's total revenue amounted to 615 million RMB, reflecting a year-on-year growth of 7.24% [1] Group 2 - The net profit attributable to the parent company was reported at -99.9825 million RMB, which represents a significant year-on-year increase of 76.93% [1] - Lakeshore Biosciences is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Insights - Lakeshore Biotech (LSB) experienced a stock price increase of 3.67%, reaching $0.819 per share with a total market capitalization of $33.75 million as of August 16 [1] - As of March 31, 2025, Lakeshore Biotech reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company recorded a net profit attributable to shareholders of -99.98 million RMB, which represents a significant year-on-year increase of 76.93% [1] - Lakeshore Biotech is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotech Co., Ltd., which focuses on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Biotech (LSB) has shown a positive market performance with a 3.13% increase in stock price, reaching $0.79 per share, and a total market capitalization of $32.55 million [1] Financial Performance - As of March 31, 2025, Lakeshore Biotech reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a significant increase in net profit attributable to shareholders, amounting to -99.98 million RMB, which represents a year-on-year growth of 76.93% [1] Company Overview - Lakeshore Biotech is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotech Co., Ltd. [1] - Beijing Yisheng Biotech Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Biosciences (LSB) has shown a positive stock performance with a 2.38% increase, reaching $0.829 per share, and a total market capitalization of $34.18 million [1] Financial Performance - As of March 31, 2025, Lakeshore Biosciences reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a net loss attributable to shareholders of 99.98 million RMB, which represents a significant year-on-year improvement of 76.93% [1] Company Overview - Lakeshore Biosciences is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Bio (LSB) experienced a significant stock price increase of 10.73%, reaching $0.775 per share, with a total market capitalization of $31.94 million as of August 12 [1] Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company recorded a net loss attributable to shareholders of 99.98 million RMB, which represents a year-on-year improvement of 76.93% [1] Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Bio (LSB) shows a positive market response with a 3.03% increase in stock price, reflecting investor confidence in the company's financial performance and growth potential [1]. Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, representing a year-on-year growth of 7.24% [1]. - The company achieved a net profit attributable to shareholders of -99.98 million RMB, which indicates a significant year-on-year increase of 76.93% [1]. Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1]. - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1].

Core Viewpoint - Lakeshore Bio (LSB) shows a positive market performance with a 2.49% increase in stock price, reaching $0.679 per share, and a total market capitalization of $27.9834 million [1] Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a significant increase in net profit attributable to shareholders, amounting to -99.9825 million RMB, which represents a year-on-year growth of 76.93% [1] Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Group 1 - The stock price of Lakeshore Biosciences (LSB) increased by 19.17% on August 1, reaching $0.90 per share, with a trading volume of $43,400 and a total market capitalization of $37.09 million [1] - As of September 30, 2024, Lakeshore Biosciences reported total revenue of 372 million RMB, representing a year-on-year growth of 36.2% [1] - The net profit attributable to the parent company was 20.58 million RMB, showing a significant year-on-year increase of 111.79% [1] Group 2 - Lakeshore Biosciences is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...